The authors have used both functional and binding studies to fully characterize the prostanoid TP receptor in the myometrium from nonpregnant human donors.Both U-46,619 and I-BOP produced concentration-dependent contraction of human myometrial strips in vitro (pEC50 = 6.9; and 7.8, resp.).U-46,619-induced contractions were attenuated by the TP receptor antagonists: ICI 192,605, ICI D1,542, L670,596, GR 32,191, SQ 29,548, ONO 3708, and BM 13,505.The binding of [125I]-BOP to human myometrial membranes was saturable, selective and displaceable.Equilibrium binding of [125I]-BOP identified one class of sites, Kd = 3.4 nM (pKd = 8.7) and a maximum binding of 323.1 fmol/mg protein.The addition of the nonhydrolyzable GTP analog GTPγS (100 μM) to the assay had no effect on [125I]-BOP binding.The Kd determined kinetically was 4.1 nM.TP receptor antagonists competed for [125I]-BOP binding: ICI D1,542 (pIC50 = 8.3) L670,596 (pIC50 = 7.9) ICI 192,605 (pIC50 = 7.5) ONO 3708 (pIC50 = 7.2) SQ 29,548 (pIC50 = 7.2) GR 32,191 (pIC50 = 7.0) and BM 13,505 (pIC50 = 6.8).The rank order of potency for the seven TP receptor antagonists in displacing [125I]-BOP from its binding site was correlated (r = 0.75) with the rank order of potency in inhibiting U-46,619-induced contraction of myometrial strips.Ligands selective for other prostanoid receptors were unable to significantly displace [125I]-BOP binding.These results are consistent with the notion that the human myometrial TP receptor is pharmacol. similar to the low affinity TP receptor in human platelets.